Literature DB >> 11913922

Evidence of human metapneumovirus in Australian children.

Michael D Nissen, David J Siebert, Ian M Mackay, Theo P Sloots, Stephen J Withers.   

Abstract

Entities:  

Mesh:

Year:  2002        PMID: 11913922      PMCID: PMC7168395          DOI: 10.5694/j.1326-5377.2002.tb04354.x

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


× No keyword cloud information.
to the editor: We wish to report the identification of a novel virus causing lower respiratory tract disease in Australian children. The presence of this virus was recently described in Dutch children and tentatively called human metapneumovirus (hMPV). Clinical symptoms of infection are reported to resemble those of human respiratory syncytial virus (hRSV) infection. We therefore investigated whether the virus was present in Australian children. Three isolates were identified from a random selection of 200 nasopharyngeal aspirate (NPA) specimens collected throughout 2001 from children presenting to the Royal Children's Hospital, Brisbane, or the Logan Hospital, a public hospital to the south of Brisbane, with clinical respiratory tract disease. All NPA specimens were initially negative for hRSV, influenza A and B, parainfluenza 1, 2 and 3 and adenovirus by direct fluorescent antigen testing and subsequent viral culture. These negative NPA specimens were then screened by polymerase chain reaction (PCR) for hMPV, based on the known sequence of the virus. Sequencing of the PCR product in all three positive samples was 100% homologous with the known hMPV sequence. Viral growth was subsequently detected in culture from two of these samples, and confirmed as hMPV, using the method of van den Hoogen et al. Co‐existent infection with coronavirus, rhinovirus, Bordetella pertussis, Chlamydia pneumoniae and Mycoplasma pneumoniae was excluded by PCR screening of the three hMPV isolates using validated in‐house methods based on established protocols. Clinical features of the infected children are summarised in the Box.

Clinical features of human metapneumovirus in three Australian children

Case 1 (Girl, 12 months) Case 2 (Boy, 5 years 11 months) Case 3 (Boy, 20 months) Date of nasopharyngeal aspirate collection 17/2/01 21/3/01 11/5/01 Presenting symptoms Rhinorrhoea, cough, tachypnoea, wheeze, vomiting Rhinorrhoea, cough, pharyngitis, conjunctivitis Rhinorrhoea, cough, fever Symptom duration before presentation (days) 4 3 4 Clinical signs Respiratory distress with hypoxia, rhinorrhoea, pharyngitis, chest wheeze with crackles Pharyngitis, chest wheeze Rhinorrhoea, pharyngitis, chest wheeze, cervical lymphadenopathy Chest X‐ray Not performed Bilateral parahilar pneumonic infiltrates Bilateral parahilar pneumonic infiltrates Clinical diagnosis Bronchiolitis Viral lower respiratory tract infection Viral lower respiratory tract infection Outcome Admitted for oxygen therapy and nasal suctioning for three days Symptomatic treatment at home Symptomatic treatment at home This is the first report of the presence of hMPV infection in Australian children and describes a new viral respiratory syndrome. It also adds to the clinical spectrum and understanding of respiratory viruses causing acute bronchiolitis in children. Only 25%–33% of NPA specimens collected from our population with suspected respiratory tract disease yield a positive result for a known viral or bacterial pathogen. Clinical features in this small cohort are difficult to separate retrospectively from hRSV. Based on the findings of this limited preliminary study of children presenting to hospital with respiratory tract symptoms, we would predict that hMPV is also relatively common in the Australian community. We are currently undertaking further characterisation of the hMPV isolates, a more detailed study of the epidemiology of hMPV disease, as well as developing improved diagnostic assays to rapidly identify clinical cases and assess seroprevalence of immunity to hMPV.

Case 1

(Girl, 12 months)

Case 2

(Boy, 5 years 11 months)

Case 3

(Boy, 20 months)

Date of nasopharyngeal aspirate collection

17/2/01

21/3/01

11/5/01

Presenting symptoms

Rhinorrhoea, cough, tachypnoea, wheeze, vomiting

Rhinorrhoea, cough, pharyngitis, conjunctivitis

Rhinorrhoea, cough, fever

Symptom duration before presentation (days)

4

3

4

Clinical signs

Respiratory distress with hypoxia, rhinorrhoea, pharyngitis, chest wheeze with crackles

Pharyngitis, chest wheeze

Rhinorrhoea, pharyngitis, chest wheeze, cervical lymphadenopathy

Chest X‐ray

Not performed

Bilateral parahilar pneumonic infiltrates

Bilateral parahilar pneumonic infiltrates

Clinical diagnosis

Bronchiolitis

Viral lower respiratory tract infection

Viral lower respiratory tract infection

Outcome

Admitted for oxygen therapy and nasal suctioning for three days

Symptomatic treatment at home

Symptomatic treatment at home

  1 in total

1.  A newly discovered human pneumovirus isolated from young children with respiratory tract disease.

Authors:  B G van den Hoogen; J C de Jong; J Groen; T Kuiken; R de Groot; R A Fouchier; A D Osterhaus
Journal:  Nat Med       Date:  2001-06       Impact factor: 53.440

  1 in total
  77 in total

1.  Real-time reverse transcriptase PCR assay for detection of human metapneumoviruses from all known genetic lineages.

Authors:  Jeroen Maertzdorf; Chiaoyin K Wang; Jennifer B Brown; Joseph D Quinto; Marla Chu; Miranda de Graaf; Bernadette G van den Hoogen; Richard Spaete; Albert D M E Osterhaus; Ron A M Fouchier
Journal:  J Clin Microbiol       Date:  2004-03       Impact factor: 5.948

2.  Detection and genetic diversity of human metapneumovirus in hospitalized children with acute respiratory infections in India.

Authors:  Sagarika Banerjee; Wayne M Sullender; Avinash Choudekar; Cherian John; Vikas Tyagi; Karen Fowler; Elliot J Lefkowitz; Shobha Broor
Journal:  J Med Virol       Date:  2011-10       Impact factor: 2.327

3.  Effects of aging on the adaptive immune response to respiratory virus infections.

Authors:  Ross B Fulton; Steven M Varga
Journal:  Aging health       Date:  2009-12-01

4.  Characterization of human metapneumovirus F protein-promoted membrane fusion: critical roles for proteolytic processing and low pH.

Authors:  Rachel M Schowalter; Stacy E Smith; Rebecca Ellis Dutch
Journal:  J Virol       Date:  2006-09-13       Impact factor: 5.103

Review 5.  Vaccines for the common cold.

Authors:  Daniel Simancas-Racines; Juan Va Franco; Claudia V Guerra; Maria L Felix; Ricardo Hidalgo; Maria José Martinez-Zapata
Journal:  Cochrane Database Syst Rev       Date:  2017-05-18

6.  Human metapneumovirus infections--biannual epidemics and clinical findings in children in the region of Basel, Switzerland.

Authors:  Ulrich Heininger; Anna Tina Kruker; Jan Bonhoeffer; Urs B Schaad
Journal:  Eur J Pediatr       Date:  2009-02-24       Impact factor: 3.183

7.  Effects of human metapneumovirus and respiratory syncytial virus antigen insertion in two 3' proximal genome positions of bovine/human parainfluenza virus type 3 on virus replication and immunogenicity.

Authors:  Roderick S Tang; Jeanne H Schickli; Mia MacPhail; Fiona Fernandes; Leenas Bicha; Joshua Spaete; Ron A M Fouchier; Albert D M E Osterhaus; Richard Spaete; Aurelia A Haller
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

Review 8.  Animal pneumoviruses: molecular genetics and pathogenesis.

Authors:  Andrew J Easton; Joseph B Domachowske; Helene F Rosenberg
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

9.  Seroepidemiology of human metapneumovirus (hMPV) on the basis of a novel enzyme-linked immunosorbent assay utilizing hMPV fusion protein expressed in recombinant vesicular stomatitis virus.

Authors:  Jessica Leung; Frank Esper; Carla Weibel; Jeffrey S Kahn
Journal:  J Clin Microbiol       Date:  2005-03       Impact factor: 5.948

10.  T lymphocytes contribute to antiviral immunity and pathogenesis in experimental human metapneumovirus infection.

Authors:  Deepthi Kolli; Efthalia L Bataki; Leanne Spetch; Antonieta Guerrero-Plata; Alan M Jewell; Pedro A Piedra; Gregg N Milligan; Roberto P Garofalo; Antonella Casola
Journal:  J Virol       Date:  2008-06-18       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.